Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

eluxadoline

Known as: 5-({(4-carbamoyl-2,6-dimethyl-L-phenylalanyl)[(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
  • B. Lacy
  • Alimentary pharmacology & therapeutics
  • 2018
  • Corpus ID: 52174948
Irritable bowel syndrome (IBS) is multifactorial in nature, and a wide range of therapies is available to manage symptoms of this… Expand
Review
2018
Review
2018
  • M. Simrén, J. Tack
  • Nature Reviews Gastroenterology & Hepatology
  • 2018
  • Corpus ID: 49333696
Functional bowel disorders (FBDs) are a spectrum of disorders characterized by combinations of symptoms attributable to the lower… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2017
Highly Cited
2017
Objectives:Eluxadoline is a mixed μ-opioid receptor (OR) and κ-OR agonist and δ-OR antagonist, approved for the treatment of… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
2017
2017
Objectives:Irritable bowel syndrome with diarrhea (IBS-D) is often managed with over-the-counter therapies such as loperamide… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Review
2017
Review
2017
This review introduces the principles of visceral sensation and appraises the current approaches to management of visceral pain… Expand
2017
2017
Eluxadoline is a newly approved orally administered drug used for the treatment of Irritable Bowel Syndrome with Diarrhea. It is… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2016
Highly Cited
2016
Background Effective and safe treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea. We… Expand
  • table 1
  • figure 1
  • figure 2
  • table 3
2015
2015
The effects of OATP1B1, OAT3, and MRP2 on the pharmacokinetics of eluxadoline, an oral, locally active, opioid receptor agonist… Expand
Review
2015
Review
2015
Eluxadoline (Viberzi™), developed by Actavis (now Allergan), is an orally administered, first-in-class compound that functions as… Expand
Highly Cited
2013
Highly Cited
2013
BACKGROUND & AIMS Simultaneous agonism of the μ-opioid receptor and antagonism of the δ-opioid receptor can reduce abdominal pain… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3